The partnership marks a strategic move to standardize reproductive care through the integration of robotics and physical AI. Developed by Conceivable Life Sciences, the AURA system is engineered to perceive and execute tasks within live clinical environments, effectively replacing hundreds of manual steps that typically rely on individual operator skill. Current pilot studies for the platform have already processed over 1,000 eggs and resulted in successful live births.
IVI RMA and Conceivable Life Sciences to Launch Robotic IVF in the US
A robotic shift is coming to American fertility clinics in 2027 as IVI RMA Global prepares to deploy the AURA platform, a specialized system designed to automate complex, operator-dependent stages of the IVF process while working alongside human embryologists to improve consistency and clinical precision.
Prof. Antonio Pellicer, Executive Chairman of IVI RMA Global, will join the board of Conceivable as part of the collaboration. Beyond the initial US rollout, the organizations plan to expand the technology across IVI RMA’s broader network, which spans Europe, Latin America, and the Middle East. By investing in this infrastructure, the companies aim to reduce variability in embryo quality and broaden access to high-standard fertility treatments globally.
Comments (0)
No comments yet. Be the first!